Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the sequencing of therapies in prostate cancer.
Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the sequencing of therapies in the treatment of patients with prostate cancer.
Over the last few years, a number of different therapies have been granted FDA approval in this space. The area of prostate cancer that is evolving most quickly is the sequencing and timing of treatment. Sweis says this has been an area of confusion in the past, but recent advances have improved outcomes for patients in terms of survival and disease control. Therapies that were initially FDA approved in the metastatic castration-resistant setting are now being moved earlier on in treatment. These include enzalutamide (Xtandi), apalalutamide (Erleada), and abiraterone acetate (Zytiga). Even docetaxel is being investigated in an earlier setting.
Patients with metastatic castration-sensitive prostate cancer are now being treated more aggressively, due in large part to large international studies like CHAARTED and STAMPEDE, Sweis says.